niacinamide has been researched along with Heart Failure in 36 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined the hemodynamic parameters as well as femoral arterial and venous cyclic guanosine monophosphate (cGMP) concentrations during intravenous infusion of NTG or nicorandil, a nitrate and potassium channel opener, in patients with congestive heart failure." | 9.08 | Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. ( Fukai, D; Hisanaga, T; Kinoshita, M; Maeda, K; Maeda, Y; Tsutamoto, T; Wada, A; Yoshida, S, 1995) |
| "Twenty patients with congestive heart failure and pulmonary capillary wedge pressure (PCWP) > or = 18 mm Hg were randomly assigned to nitroglycerin or nicorandil in a double-blind, crossover study." | 9.08 | Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. ( Aarsland, T; Dickstein, K; Gøransson, L; Larsen, AI; Tamby, JF, 1997) |
| "To evaluate whether hemodynamic tolerance develops to nicorandil, a nitrate and potassium channel opener, 14 patients with chronic heart failure (CHF) were treated with nicorandil and 11 were treated with nitroglycerin (GTN)." | 9.07 | Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. ( Horie, H; Kinoshita, M; Maeda, Y; Nakae, I; Tsutamoto, T; Wada, A; Yabe, T, 1994) |
| "Rest and exercise hemodynamic and hormonal effects of nicorandil, a nicotinamide-nitrate vasodilator, were assessed in 9 patients with New York Heart Association class II or III congestive heart failure (CHF) and left ventricular ejection fraction less than or equal to 40%." | 9.06 | Usefulness of nicorandil in congestive heart failure. ( Binetti, G; Boriani, G; Boschi, S; Galié, N; Magnani, B; Maiello, L; Varani, E, 1990) |
| "Twenty-five patients with congestive heart failure (CHF) underwent a double-blind randomized study of the acute hemodynamic effects of orally administered nicorandil, a newly developed vasodilator drug." | 9.06 | Hemodynamic effects of oral nicorandil in congestive heart failure. ( Binkley, PF; Cody, RJ; Leier, CV; Moeschberger, ML; Mohrland, JS; Tice, FD; Wolf, DL, 1990) |
| "Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF)." | 7.70 | Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim. ( Koyama, T; Matsuzaki, T; Nakasone, J; Noguchi, K; Ojiri, Y; Sakanashi, M, 1998) |
| "Nicorandil is a nicotinamide derivative with a potential role in human therapeutics because of its potent vasodilating properties." | 6.67 | Clinical pharmacology of nicorandil in patients with congestive heart failure. ( Bindley, PF; Binkley, PF; Jungbluth, GL; Leier, CV; MacKichan, JJ; Mohrland, JS; Tice, FD; Wolf, DL, 1992) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | 6.45 | Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. ( Jarkowski, A; Wong, MK, 2009) |
| "Heart failure was produced by myocardial infarction, and was associated with markedly increased AMPK and SIRT1 protein levels." | 5.40 | Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. ( Gu, XS; Lei, JP; Li, L; Su, DF; Wang, ZB; Ye, Z; Zheng, X, 2014) |
| "Suddenly, he developed left cardiac failure, and he died 6 days later through a rapid clinical course that included circulatory failure, abnormal glucose tolerance, disseminated intravascular coagulation, and multiple organ failure." | 5.38 | [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. ( Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M, 2012) |
| "Nicorandil is a vasodilator drug that combines potassium channel opening properties with nitrate effects." | 5.28 | Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. ( Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992) |
| "Nicorandil is a new compound that has shown potent vasodilator activities on venous and arterial beds in experimental pharmacology." | 5.28 | Hemodynamic action of nicorandil in chronic congestive heart failure. ( Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989) |
| " We examined the hemodynamic parameters as well as femoral arterial and venous cyclic guanosine monophosphate (cGMP) concentrations during intravenous infusion of NTG or nicorandil, a nitrate and potassium channel opener, in patients with congestive heart failure." | 5.08 | Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. ( Fukai, D; Hisanaga, T; Kinoshita, M; Maeda, K; Maeda, Y; Tsutamoto, T; Wada, A; Yoshida, S, 1995) |
| "Twenty patients with congestive heart failure and pulmonary capillary wedge pressure (PCWP) > or = 18 mm Hg were randomly assigned to nitroglycerin or nicorandil in a double-blind, crossover study." | 5.08 | Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. ( Aarsland, T; Dickstein, K; Gøransson, L; Larsen, AI; Tamby, JF, 1997) |
| "To evaluate whether hemodynamic tolerance develops to nicorandil, a nitrate and potassium channel opener, 14 patients with chronic heart failure (CHF) were treated with nicorandil and 11 were treated with nitroglycerin (GTN)." | 5.07 | Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. ( Horie, H; Kinoshita, M; Maeda, Y; Nakae, I; Tsutamoto, T; Wada, A; Yabe, T, 1994) |
| "Rest and exercise hemodynamic and hormonal effects of nicorandil, a nicotinamide-nitrate vasodilator, were assessed in 9 patients with New York Heart Association class II or III congestive heart failure (CHF) and left ventricular ejection fraction less than or equal to 40%." | 5.06 | Usefulness of nicorandil in congestive heart failure. ( Binetti, G; Boriani, G; Boschi, S; Galié, N; Magnani, B; Maiello, L; Varani, E, 1990) |
| "Twenty-five patients with congestive heart failure (CHF) underwent a double-blind randomized study of the acute hemodynamic effects of orally administered nicorandil, a newly developed vasodilator drug." | 5.06 | Hemodynamic effects of oral nicorandil in congestive heart failure. ( Binkley, PF; Cody, RJ; Leier, CV; Moeschberger, ML; Mohrland, JS; Tice, FD; Wolf, DL, 1990) |
| "The data show that nicotinamide riboside, the most energy-efficient among NAD precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease with few therapeutic options." | 3.88 | Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. ( Baczkó, I; Blanc, J; Brenner, C; Breton, M; Decaux, JF; Deloux, R; Diguet, N; Garnier, A; Gouge, A; Gressette, M; Lavery, GG; Li, Z; Manoury, B; Mericskay, M; Mougenot, N; Piquereau, J; Tannous, C; Trammell, SAJ; Zoll, J, 2018) |
| "Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF)." | 3.70 | Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim. ( Koyama, T; Matsuzaki, T; Nakasone, J; Noguchi, K; Ojiri, Y; Sakanashi, M, 1998) |
| "Nicorandil is a nicotinamide derivative with a potential role in human therapeutics because of its potent vasodilating properties." | 2.67 | Clinical pharmacology of nicorandil in patients with congestive heart failure. ( Bindley, PF; Binkley, PF; Jungbluth, GL; Leier, CV; MacKichan, JJ; Mohrland, JS; Tice, FD; Wolf, DL, 1992) |
| "Treatment of breast cancer (BC) has changed over the last decade with the advent of targeted therapies." | 2.47 | Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. ( Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A, 2011) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | 2.45 | Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. ( Jarkowski, A; Wong, MK, 2009) |
| "Increasing use of targeted anticancer agents that inhibit tyrosine kinase signaling (monoclonal antibodies or tyrosine kinase inhibitors) has dramatically improved the survival of patients with malignancies." | 2.45 | Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. ( Chen, MH, 2009) |
| "Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases." | 1.46 | Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. ( Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H, 2017) |
| "Heart failure was produced by myocardial infarction, and was associated with markedly increased AMPK and SIRT1 protein levels." | 1.40 | Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. ( Gu, XS; Lei, JP; Li, L; Su, DF; Wang, ZB; Ye, Z; Zheng, X, 2014) |
| "Suddenly, he developed left cardiac failure, and he died 6 days later through a rapid clinical course that included circulatory failure, abnormal glucose tolerance, disseminated intravascular coagulation, and multiple organ failure." | 1.38 | [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. ( Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M, 2012) |
| "DOX-induced heart failure is thought to be caused by reduction/oxidation cycling of DOX to generate oxidative stress and cardiomyocyte cell death." | 1.35 | Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. ( Bennett, JA; Danz, ED; Henry, N; Keller, RS; Skramsted, J, 2009) |
| "NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion." | 1.33 | Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor. ( Kakefuda, A; Kuramochi, T; Sakamoto, S; Taguchi, T; Tsukamoto, I; Yamada, H, 2005) |
| "Nicorandil is a vasodilator drug that combines potassium channel opening properties with nitrate effects." | 1.28 | Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. ( Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992) |
| "Nicorandil is a new compound that has shown potent vasodilator activities on venous and arterial beds in experimental pharmacology." | 1.28 | Hemodynamic action of nicorandil in chronic congestive heart failure. ( Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.67) | 18.7374 |
| 1990's | 10 (27.78) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, B | 1 |
| Wang, DD | 1 |
| Qiu, Y | 1 |
| Airhart, S | 1 |
| Liu, Y | 1 |
| Stempien-Otero, A | 1 |
| O'Brien, KD | 1 |
| Tian, R | 2 |
| Kimura, G | 1 |
| Kataoka, M | 1 |
| Inami, T | 1 |
| Fukuda, K | 1 |
| Yoshino, H | 1 |
| Satoh, T | 1 |
| Diguet, N | 1 |
| Trammell, SAJ | 1 |
| Tannous, C | 1 |
| Deloux, R | 1 |
| Piquereau, J | 1 |
| Mougenot, N | 2 |
| Gouge, A | 1 |
| Gressette, M | 1 |
| Manoury, B | 1 |
| Blanc, J | 1 |
| Breton, M | 1 |
| Decaux, JF | 1 |
| Lavery, GG | 1 |
| Baczkó, I | 1 |
| Zoll, J | 1 |
| Garnier, A | 1 |
| Li, Z | 1 |
| Brenner, C | 1 |
| Mericskay, M | 2 |
| Walker, MA | 1 |
| Vignier, N | 1 |
| Chatzifrangkeskou, M | 1 |
| Morales Rodriguez, B | 1 |
| Wahbi, K | 1 |
| Bonne, G | 1 |
| Muchir, A | 1 |
| Gu, XS | 1 |
| Wang, ZB | 1 |
| Ye, Z | 1 |
| Lei, JP | 1 |
| Li, L | 1 |
| Su, DF | 1 |
| Zheng, X | 1 |
| Pitoia, F | 1 |
| Ruan, Y | 1 |
| Dong, C | 1 |
| Patel, J | 1 |
| Duan, C | 1 |
| Wang, X | 1 |
| Wu, X | 1 |
| Cao, Y | 1 |
| Pu, L | 1 |
| Lu, D | 1 |
| Shen, T | 1 |
| Li, J | 1 |
| Haas, NB | 1 |
| Manola, J | 1 |
| Ky, B | 1 |
| Flaherty, KT | 1 |
| Uzzo, RG | 1 |
| Kane, CJ | 1 |
| Jewett, M | 1 |
| Wood, L | 1 |
| Wood, CG | 1 |
| Atkins, MB | 1 |
| Dutcher, JJ | 1 |
| Wilding, G | 1 |
| DiPaola, RS | 1 |
| Imran, TF | 1 |
| Shah, R | 1 |
| Ha, AS | 1 |
| Thomas, R | 1 |
| Joseph, J | 1 |
| ARCHI, G | 1 |
| TINACCI, F | 1 |
| Danz, ED | 1 |
| Skramsted, J | 1 |
| Henry, N | 1 |
| Bennett, JA | 1 |
| Keller, RS | 1 |
| Wong, MK | 1 |
| Jarkowski, A | 1 |
| Chen, MH | 1 |
| Livanov, GA | 1 |
| Amagyrov, VP | 1 |
| Batotsyrenov, BV | 1 |
| Lodiagin, AN | 1 |
| Batotsyrenova, KhV | 1 |
| Zambelli, A | 1 |
| Della Porta, MG | 1 |
| Eleuteri, E | 1 |
| De Giuli, L | 1 |
| Catalano, O | 1 |
| Tondini, C | 1 |
| Riccardi, A | 1 |
| Geisberg, C | 1 |
| Pentassuglia, L | 1 |
| Sawyer, DB | 1 |
| Kimura, T | 1 |
| Suetomi, T | 1 |
| Miyagawa, T | 1 |
| Tsutsumi, M | 1 |
| Rose, S | 1 |
| RE, A | 1 |
| Alcendor, RR | 1 |
| Kirshenbaum, LA | 1 |
| Imai, S | 1 |
| Vatner, SF | 1 |
| Sadoshima, J | 1 |
| Kuramochi, T | 1 |
| Kakefuda, A | 1 |
| Yamada, H | 1 |
| Tsukamoto, I | 1 |
| Taguchi, T | 1 |
| Sakamoto, S | 1 |
| Bachert, EL | 1 |
| Fung, HL | 1 |
| Tsutamoto, T | 2 |
| Kinoshita, M | 2 |
| Hisanaga, T | 1 |
| Maeda, Y | 2 |
| Maeda, K | 1 |
| Wada, A | 2 |
| Fukai, D | 1 |
| Yoshida, S | 1 |
| Nakae, I | 1 |
| Yabe, T | 1 |
| Horie, H | 1 |
| Satoh, K | 1 |
| Larsen, AI | 1 |
| Gøransson, L | 1 |
| Aarsland, T | 1 |
| Tamby, JF | 1 |
| Dickstein, K | 1 |
| Noguchi, K | 1 |
| Matsuzaki, T | 1 |
| Ojiri, Y | 1 |
| Koyama, T | 1 |
| Nakasone, J | 1 |
| Sakanashi, M | 1 |
| Giles, TD | 1 |
| Pina, IL | 1 |
| Quiroz, AC | 1 |
| Roffidal, L | 1 |
| Zaleski, R | 1 |
| Porter, RS | 1 |
| Karalis, DG | 1 |
| Mohrland, JS | 3 |
| Wolf, DL | 3 |
| Hearron, AE | 1 |
| Tice, FD | 2 |
| Jungbluth, GL | 1 |
| Binkley, PF | 2 |
| MacKichan, JJ | 1 |
| Leier, CV | 2 |
| Bindley, PF | 1 |
| Galié, N | 1 |
| Varani, E | 1 |
| Maiello, L | 1 |
| Boriani, G | 1 |
| Boschi, S | 1 |
| Binetti, G | 1 |
| Magnani, B | 1 |
| Cody, RJ | 1 |
| Moeschberger, ML | 1 |
| Solal, AC | 1 |
| Jaeger, P | 1 |
| Bouthier, J | 1 |
| Juliard, JM | 1 |
| Dahan, M | 1 |
| Gourgon, R | 1 |
| Nurmukhambetov, AN | 1 |
| Riabtseva, TA | 1 |
| Bosisio, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Preoperative Nicotinamide Riboside (Vitamin B3) Supplementation in Patients Undergoing Elective Left Ventricular Assist Device (LVAD) Implantation[NCT03727646] | Early Phase 1 | 5 participants (Actual) | Interventional | 2018-09-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Heart Failure
| Article | Year |
|---|---|
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2009 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agent | 2012 |
[Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
Topics: Animals; Benzopyrans; Calcium Channel Blockers; Cromakalim; Guanidines; Heart Failure; Hemodynamics; | 1993 |
8 trials available for niacinamide and Heart Failure
| Article | Year |
|---|---|
Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure.
Topics: Female; Heart Failure; Humans; Inflammation; Leukocytes, Mononuclear; Male; Mitochondria, Heart; Mod | 2020 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Ad | 2015 |
Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Cyclic GMP; Female; Heart Failure; Hemodynamics; | 1995 |
Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure.
Topics: Adult; Aged; Atrial Natriuretic Factor; Drug Tolerance; Female; Heart Failure; Hemodynamics; Humans; | 1994 |
Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Infusion | 1997 |
Clinical pharmacology of nicorandil in patients with congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Cardiovascular System; Double-Blind Method; | 1992 |
Usefulness of nicorandil in congestive heart failure.
Topics: Adult; Double-Blind Method; Exercise; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Ma | 1990 |
Hemodynamic effects of oral nicorandil in congestive heart failure.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; | 1990 |
23 other studies available for niacinamide and Heart Failure
| Article | Year |
|---|---|
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary H | 2017 |
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy.
Topics: Acrylamides; AMP-Activated Protein Kinases; Animals; Cardiomyopathy, Dilated; Citric Acid; Cytokines | 2018 |
Raising NAD in Heart Failure: Time to Translate?
Topics: Animals; Cardiomyopathy, Dilated; Heart Failure; Mice; NAD; Niacinamide; Pyridinium Compounds | 2018 |
Rescue of biosynthesis of nicotinamide adenine dinucleotide protects the heart in cardiomyopathy caused by lamin A/C gene mutation.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Heart; Heart Failure; Heart Ventricles; Humans; L | 2018 |
Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Cells, Cultured; Heart Failure; Male; Mice; Myoca | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; | 2014 |
SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways.
Topics: Animals; Apoptosis; Cell Line; Doxorubicin; Gene Expression Regulation; Heart Failure; Humans; Mice; | 2015 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niaci | 2016 |
On the action of nicotinic amide in the liver due to stasis (heart failure).
Topics: Heart Failure; Liver Diseases; Niacin; Niacinamide | 1948 |
Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway.
Topics: Animals; Cardiotonic Agents; Cell Death; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; | 2009 |
[Pharmacological correction of hypoxic and free-radical disorders in patients with acute myocardial infarction complicated by acute heart failure].
Topics: Acute Disease; Critical Care; Drug Combinations; Flavin Mononucleotide; Fluorocarbons; Free Radicals | 2010 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intole | 2012 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; H | 2013 |
[Combined adenosinetriphosphoric acid, cocarboxylase, vitamin B12 and nicotinamide in therapy of congestive heart failure; first clinical trials].
Topics: Adenosine Triphosphate; Corrinoids; Heart Failure; Hematinics; Humans; Niacin; Niacinamide; Nicotini | 1959 |
Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes.
Topics: Acetylation; Alkaloids; Animals; Apoptosis; Atrial Natriuretic Factor; Benzamides; Benzophenanthridi | 2004 |
Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Calcium; Calcium Channel Blockers; Cytochrom | 2005 |
Hemodynamic tolerance and pharmacokinetics of nicorandil in experimental heart failure.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Chromatography, High Pressure Liquid; Heart Failur | 1993 |
Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim.
Topics: Acute Disease; Animals; Blood Pressure; Coronary Circulation; Cromakalim; Disease Models, Animal; Do | 1998 |
Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Topics: Aged; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rate; | 1992 |
A symposium: A new treatment for angina pectoris and heart failure. October 17, 1987, San Francisco. Proceedings.
Topics: Angina Pectoris; Animals; Heart Failure; Humans; Niacinamide; Nicorandil; Vasodilator Agents | 1989 |
Hemodynamic action of nicorandil in chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Female; Heart Failure; Heart Rate; Hem | 1989 |
[Prevention of disorders of cardiac contractility with nicotinamide in adriblastin -related damage].
Topics: Animals; Cardiomyopathies; Doxorubicin; Heart Failure; Hypoxia; Myocardial Contraction; Niacinamide; | 1988 |
[Action of a new choleretic associated with a spasmolytic and with vitamin B 1 and vitamin PP in therapy of some hepato-biliary disease conditions].
Topics: Adult; Aged; Biliary Dyskinesia; Cholagogues and Choleretics; Female; Heart Failure; Humans; Male; M | 1967 |